Product
Supplier
Encyclopedia
Inquiry
Sichuan Duorui - Pegcetacoplan buy - large image1
Sichuan Duorui - Pegcetacoplan buy - image1

Sichuan Duorui - Pegcetacoplan

GMP COA

Unit Price: Get Latest Price
CAS No.:

2019171-69-6

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Chengdu

Packaging:

depends on customers' needs

Price valid (until):

2026-02-28

Company Type:
Manufactory
Location:
China
Qualification:
Main Products:

Semaglutide,Tirzepatide,Retatrutide,Lanreotide Acetate,Pegcetacoplan

  • Product Description

  • Seller Information

  • History Price

  • Description


      Product Detail  


    Pegcetacoplan injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH)

    Pegcetacoplan is the first FDA-approved drug as a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

    Please feel free to contact us if you need COA.

    Contact Person:Delia Zhong

    Wechat/Tel:  +86 184 8235 1102

    E-mail:deliazhong@duoruipharm.com

    Website:https://www.duoruibiopharm.com


    Certificates

    Basic Info
    Product Name:

    Pegcetacoplan

    CAS No.:

    2019171-69-6

    Categories:

    Other Chemical Drugs

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    Semaglutide,Tirzepatide,Retatrutide,Lanreotide Acetate,Pegcetacoplan

    Location:

    No. 76 Jinle Road, Chengdu-Aba Industrial Concentration Development Zone, Jintang County, Chengdu City, Sichuan Province, China

    Payment Terms:

    TT against copy of documents,L/C,100% TT in advance

    Total Annual Revenue:

    $5 million-$10 million

    Total Employees:

    101-200

    Year of Establishment:

    2018

    Established in 2018 and located in Jintang County, Chengdu, Sichuan Province, focuses on the R&D and production of peptide APIs. The company covers an area of ​​200,000 square meters, has a GMP production workshop, possesses advanced peptide drug preparation technology, and has large-scale peptide production capabilities, providing high-quality, low-cost, and fast-response product services.

    Main products: Lanreotide Acetate, Semaglutide, Tirzepatide, Retatrutide, Teriparatide, etc.

    Capacity:
    Peptide for human use: 500 kg
    Peptide for Veterinary use: 200 kg

    Oct., 2024: "Albuvirtide" API passed the NMPA GMP compliance inspection.
    Aug. 2023: "Teriparatide" Injection"assembly line passed US FDA site inspection with no 483 observation.

  • Weekly Price

    The chart shows the price trend of the product in the past 12 months.

  • Country Product Purchase Quantity Date Posted
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.